CancerLinQ and Precision HealthAI have recently joined hands with Tempus to analyze troves of recent cancer patients’ information owned by CancerLinQ. The trio hopes to advance the field of oncology, its common treatments, and rates of prognosis with its detailed, in-depth analysis of information pulled from some of the world’s most popular, advanced clinics, hospitals, and cancer treatment specialists.
ASCO founded CancerLinQ just a few years ago. Both parent and subsidiary had intended on CancerLinQ scrounging up and holding tons of patients’ information, most or all of which were expected to be related to cancer, although weren’t sure of CancerLinQ’s ability to analyze and make inferences from such information.
Chief Executive Officer of ASCO, Dr. Clifford Hudis, recenlty stated that the arrangement between the three companies is “practical,” as Tempus and Precision HealthAI are slated to run through CancerLinQ’s hordes of information far more quickly than without each other’s help. CancerLInQ is fortunate to work with two companies highly skilled at making sense of cancer patients’ intimate details, in the sense of society’s general treatment of cancer and its carriers, as the subsidiary couldn’t hope to analyze the information it’s purchased itself.
The work that Tempus, CancerLinQ, and Precision HealthAI publish could help drug companies develop more effective clinical trials, pharmaceutical companies more readily develop and test new drugs, and provide meaningful inferences of CancerLinQ’s information to oncologists around the world.
Tempus was made by Eric Lefkofsky and Brad Keywell in 2015. Still home to Chicago, Illinois, Tempus relies on its full-fledged data pipelines to insource, handle, and process data, all of which is related to the clinical practice of medicine, human science, and molecular data sourced from the world’s leading scientists.
Mr. Lefkofsky resigned from his role as Chief Executive Office of Groupon to found Tempus. Citing the reason for creating Tempus as being forced to watch a close family member face the perils of cancer, and then realizing the current state of oncology didn’t support the treatment of the all-too-deadly disease with all the advanced technology the world offered.
With the fire of the world behind him, Eric Lefkofsky has combined the worlds of healthcare with technology, utilizing some of the market’s sharpest, most cutting-edge genomic sequencing and analytical tools.
About Eric Lefkofsky
Eric Lefkofsky is one of the United States’ biggest names when it comes to entrepreneurship, starting businesses, and large, technological corporations. Lefkofsky was initially interested in being a lawyer, attending both undergraduate and law school at the prestigious University of Michigan.
After graduating both programs in 1993, the young Mr. Lefkofsky decided to start his very first business with help from college classmate Brad Keywell. The pair has purchased an apparel manufacturer and brand in Madison, Wisconsin, called Brandon Apparel, with money borrowed from their closest family members.
In 1999, Lefkofsky and Keywell joined forces yet again to create Starbelly, a dot-com company that rose the dot-com bubble to success, as the pair sold the company just months before the bubble bursted. Over the years, Brad Keywell and Mr. Eric Lefkofsky have started countless businesses with the help of one another, again, and again.
Then-stranger Andrew Mason had an idea for a collective action web page titled ThePoint.com, which, after hearing about from Mason himself, decided to help fund with one million dollars’ backing, and helped co-found the business.
Just short of two years after ThePoint.com hit the World Wide Web as an active domain, it changed its name to Groupon, now recognized as one of the most popular commercial mobile applications in all of Apple, Android, and other digital application markets.